Mohammad Alghrouz, MD
Cardiovascular Disease · Beaumont, TXNPI 1184983686
Payments from drug & device makers
Across 231 payments — averaging $48.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$1K
- Cardiovascular Systems Inc.$829
- Medtronic$799
- Novartis$315
- Abiomed$282
- plus $3K from 28 others
What the payments were for
- Travel & lodging$5,25547%
- Food & beverage$5,90753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 45 | $5,225 |
| Boston Scientific | 33 | $1,001 |
| Cardiovascular Systems Inc. | 2 | $829 |
| Medtronic | 8 | $799 |
| Novartis | 19 | $315 |
| Abiomed | 5 | $282 |
| Johnson & Johnson | 16 | $271 |
| Merck | 12 | $259 |
| Amgen | 14 | $258 |
| Pfizer | 12 | $223 |
| Edwards Lifesciences | 3 | $169 |
| E.r. Squibb & Sons, L.L.C. | 12 | $157 |
| Shockwave Medical, Inc | 2 | $153 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $149 |
| Inari Medical, Inc. | 3 | $136 |
| Actelion Pharmaceuticals US, Inc. | 7 | $127 |
| Penumbra, Inc. | 1 | $112 |
| Baxter Healthcare | 3 | $99 |
| Biotronik Inc. | 2 | $95 |
| Lexicon Pharmaceuticals, Inc. | 4 | $73 |
| Inspire Medical Systems, Inc. | 1 | $63 |
| Stryker | 2 | $53 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Cleerly, Inc. | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $38 |
| Angiodynamics, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Boehringer Ingelheim | 1 | $23 |
| Cagent Vascular Inc | 1 | $22 |
| Convatec Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Medicomp Inc | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Heartflow, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE SKYPOINT$1,867
- QUADRA ALLURE MP$1,021
- Diamondback Peripheral$762
- PERCLOSE PROGLIDE$756
- Micra$637
- ACCENT$539
- DRAGONFLY OPSTAR$141
- Impella$133
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$129
- Watchman$120
- AVEIR$114
- Indigo System$112
- SYNERGY$108
How this compares
$11,163 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $201,338 |
| FarxigaDapagliflozin Propanediol | 37 | $40,959 |
| Repatha SureclickEvolocumab | 18 | $13,153 |
| XareltoRivaroxaban | 12 | $12,656 |
| JardianceEmpagliflozin | 13 | $11,891 |
| BrilintaTicagrelor | 19 | $9,311 |
| Ranolazine ErRanolazine | 45 | $5,993 |
| ClopidogrelClopidogrel Bisulfate | 160 | $1,878 |
| Metoprolol Succinate | 149 | $1,867 |
| Atorvastatin Calcium | 156 | $1,794 |
| Rosuvastatin Calcium | 104 | $1,638 |
| Losartan Potassium | 138 | $1,461 |
| Enoxaparin Sodium | 20 | $1,403 |
| Carvedilol | 131 | $1,299 |
| Furosemide | 233 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $201,338205 claims |
| AstraZenecaFarxiga, Brilinta | $16 | $50,27056 claims |
| Johnson & JohnsonXarelto | $271 | $12,65612 claims |
| Boehringer IngelheimJardiance | $23 | $11,89113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Beaumont
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.